Imaging Core Lab for Madrigal Pharmaceuticals Phase 2a study of MGL-3196 (MAD07)

Imaging Core Lab for Madrigal Pharmaceuticals Phase 2a study of MGL-3196 (MAD07)

Es posible que algunos contenidos no estén disponibles en español.

Study Details

Full Title

A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years with MASH with Fibrosis Stage F1-F3

Principal Investigator

Mustafa
Bashir

Protocol Number

PRO00120346

NCT ID

NA

Phase

N/A

Enrollment Status

Open to Enrollment